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J Sex MedIntroduction: Decrements in health-related quality of life (HRQOL) and sexual difﬁculties are a recognized
consequence of prostate cancer (PCa) treatment. However little is known about the experience of gay and
bisexual (GB) men.
Aim: HRQOL and psychosexual predictors of HRQOL were examined in GB and heterosexual men with PCa
to inform targeted health information and support.
Method: One hundred twenty-four GB and 225 heterosexual men with PCa completed a range of validated
psychosexual instruments.
Main outcome measure: Functional Assessment of Cancer Therapy e Prostate (FACT-P) was used to measure
HRQOL, with validated psychosexual measures, and demographic and treatment variables used as predictors.
Results: GBmen were signiﬁcantly younger (64.25 years) than heterosexual men (71.54 years), less likely to be in
an ongoing relationship, and more likely to have casual sexual partners. Compared with age-matched population
norms, participants in both groups reported signiﬁcantly lower sexual functioning and HRQOL, increased psy-
chological distress, disruptions to dyadic sexual communication, and lower masculine self-esteem, sexual conﬁ-
dence, and sexual intimacy. In comparison with heterosexual men, GB men reported signiﬁcantly lower HRQOL
(P ¼ .046), masculine self-esteem (P < .001), and satisfaction with treatment (P ¼ .013); higher psychological
distress (P ¼ .005), cancer related distress (P < .001) and ejaculatory concern (P < .001); and higher sexual
functioning (P < .001) and sexual conﬁdence (P ¼ .001). In regression analysis, psychological distress, cancer-
related distress, masculine self-esteem, and satisfaction with treatment were predictors of HRQOL for GB men
(R2Adj ¼ .804); psychological distress and sexual conﬁdence were predictors for heterosexual men (R2Adj ¼ .690).
Conclusion: These ﬁndings conﬁrm differences between GB and heterosexual men in the impact of PCa on
HRQOL across a range of domains, suggesting there is a need for GB targeted PCa information and support, to
address the concerns of this “hidden population” in PCa care.
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426 Ussher et alINTRODUCTION
Advances in preventative screening and cancer treatments have
led to a decrease in prostate cancer (PCa)mortality rates over the past
2 decades,with 5-year survival rates inAustralia currently standing at
90%.1 This has led to an interest in health-related quality of life
(HRQOL) of men treated for PCa, with prospective population-
based cohort studies2,3 reporting persistently lowered HRQOL
compared with age-matched healthy populations. Decreased sexual
functioning has been reported to be the most prevalent reduction in
HRQOL 3 years after diagnosis,4 with erectile dysfunction reported
by 77% ofmen treatedwith radical prostatectomy.2 PCa treatments
also have been associated with loss of libido, penile shortening,
nonejaculatory orgasms, or decreased orgasmic sensation, as well as
bowel and urinary incontinence.5 These sexual changes have been
associatedwith anxiety anddepression,6 challenges tomasculine self-
esteem,7 and disruptions to sexual intimacy,8 sexual conﬁdence,7
and dyadic relationship communication.9
Until recently, research examining HRQOL and sexual func-
tioning after PCa has focused on heterosexual men. This has resulted
in gay and bisexual (GB) men, conservatively estimated to make up
3% to 5% of PCa survivors,10 being described as an “invisible di-
versity,”11 or a “hidden population.”12 There have been appeals for
health providers to acknowledge that GB men may experience PCa
differently from heterosexual men, necessitating targeted informa-
tion and support.12,13 However, recent reviews of PCa educational
resources report an absence of such targeted support,14,15 leading to
calls for research to inform its future development.
There is some evidence that gay men report different impact of
PCa on HRQOL than heterosexual men, manifested in signiﬁ-
cantly greater disruptions to sexual,16 urinary, bowel and mental
functioning,17,18 greater sexual and ejaculatory bother19 and fear
of PCa recurrence,17 as well as lower masculine self-esteem and less
affection from partners.18 However, at the same time, it has also
been reported that GB men experience better sexual func-
tioning,17 or that there are no differences in sexual functioning
between GB and heterosexual men with PCa.18 Previous research
in this ﬁeld has been limited by comparing GB men to population
norms, rather than a comparative sample of heterosexual men,17,20
or utilizing small samples of GB men, thus precluding statistical
analysis.16,21 The 1 published study that compared 96 GB and
460 heterosexual men with PCa19 focused on diagnostic and
treatment differences between the 2 groups, as well as sexual
functioning, sexual bother, and depression, rather than HRQOL.AIMS
Further research is needed to examine HRQOL and psycho-
sexual predictors of HRQOL in GB men in comparison with
heterosexual men using validated psychosocial questionnaires17
to evaluate these discrepancies in the research literature, and to
inform targeted health information and support. This is the aim
of the present study. The research questions were: Are there
differences between GB and heterosexual men in HRQOL,sexual functioning, sexual conﬁdence, psychological and cancer-
related distress, masculine self-esteem, sexual intimacy, and
sexual communication? What are the psychosexual predictors of
HRQOL in GB and heterosexual men? How do levels of
HRQOL compare with norms or other matched samples?METHODS
Participants and Recruitment
Participants were recruited as part of a larger mixed methods
program of research examining HRQOL and sexual wellbeing
after PCa in GB men and their partners, in comparison with
heterosexual men. The inclusion criterion was diagnosis of PCa;
there were no additional exclusion criteria. Due to difﬁculties in
recruiting this hard-to-reach population,17 a range of recruitment
strategies were adopted simultaneously. The majority of GB men
with PCa were recruited through distribution of an information
sheet by collaborating urology and general practice clinicians, PCa
cancer support groups, and GB community organizations. An
advertisement for the study and link to the information sheet also
was posted on GB social media and on electronic listservs targeting
PCa survivors. The heterosexual comparison sample and a small
proportion of the gay sample were recruited through a distribution
of the information sheet to PCa survivors on cancer research
volunteer databases. Given the broad nature of recruitment, it is
not possible to ascertain how many men received the information
sheet or read the advertisement, in order to calculate response rate.
Ethical approval for the study was granted by Western Sydney
University Human Research Ethics Committee, with free and
informed consent obtained from all participants.MAIN OUTCOME MEASURES
Demographic and Medical Information
Participants completed a questionnaire about socio-
demographics and medical history.
Functional Assessment of Cancer Therapy e Prostate
(FACT-P)22
The Fact-P measures HRQOL in men with PCa. It consists of
the FACTeG (general), a 27-item self-report questionnaire
that measures general HRQOL in people with cancer across
4 subscales: social, physical, emotional, and day-to-day wellbeing,
as well as an additional 12-item HRQOL subscale that measures
concerns speciﬁc to PCa. The combination of the 5 subscales
makes up the FACT-P. Items are scored on a ﬁve point Likert
scale with higher scores indicating better quality of life. In the
present study, excellent internal consistency was found for the
FACT-P total score in both samples (a ¼ 0.92 respectively).Brief Symptom Inventory-18 (BSI-18)23
The BSI-18 is an18-item measure of psychological distress
comprising anxiety, depression, and somatization subscales, as wellJ Sex Med 2016;13:425e434
Comparing HRQOL of Gay/Bisexual and Heterosexual Men With Prostate Cancer 427as a global severity index (GSI). Levels of distress during the past
week are rated on a 5-point Likert scale, with higher scores indicating
greater distress. In the present study, Cronbach’s alpha was high in
both samples within each subscale and the GSI (a ¼ 0.84e0.95).Changes in Sexual Functioning Questionnaire (CSFQ-M)
The CSFQ-M is a 14-item measure of men’s sexual functioning
using a 5-point Likert scale,24 in which higher scores indicate
greater levels of reported functioning. The CSFQ-M contains 5
subscales identifying different aspects of sexual functioning: desire/
frequency; desire/interest; arousal/erection; orgasm/ejaculation;
and pleasure. In the current study, high alpha coefﬁcients for total
scores for both samples were found (a ¼ 0.90).Dyadic Sexual Communication Scale (DSC)25
The DSC is a 13-item scale assessing perceptions of the commu-
nication process within sexual relationships. A 6-point Likert scale is
used, with higher scores associated with better quality perceived
communication. Excellent internal consistency was demonstrated in
the GB (a¼ 0.89) and heterosexual (a ¼ 0.94) samples.Expanded Prostate Cancer Index (EPIC) e Sexual Domain26
The present study utilized the 13-item sexual domain ques-
tions from the Expanded Prostate Cancer Index Composite
(EPIC), an instrument designed to evaluate patient function and
bother after PCa treatment. The sexual domain is examined in 2
subscales: sexual function and sexual bother. In the current
study, Cronbach’s alpha was high for GB and heterosexual
sample total scores (a ¼ 0.92; 0.90).Memorial Anxiety Scale for Prostate Cancer (MAXePC)27
The MAX-P is an 18-item measure of PCa-related
anxiety with 3 subscales: prostate cancer anxiety, PSA anxiety,
and fear of recurrence. Items are scored on a 5-point Likert scale
with higher scores indicating greater PCa-related anxiety. In the
present study, excellent Cronbach alpha coefﬁcients of 0.92 were
found in both samples for the MAX-PC total score.Sexual Intimacy, Sexual Conﬁdence and Masculine Self-
Esteem
A subset of the Prostate Cancer-Related Quality of Life Scales
(PCaQoL Scales)25 were used to measure 3 key behavioral,
emotional, and interpersonal aspects of life affected by PCa:
sexual intimacy, sexual conﬁdence, and masculine self-esteem. In
the current study, Cronbach’s alpha were acceptable to excellent
across the 3 subscales in both samples (a ¼ 0.75e0.92).
Across the whole survey, items for GB and heterosexual par-
ticipants were equivalent, with the exception of terms such as
“male partner(s)” or “female partner(s)”, and “intercourse” or
“anal intercourse”, within each survey.J Sex Med 2016;13:425e434Procedure
Participants responded to the request for volunteers by
completing an online survey and a consent form.Statistical Analysis
GB and heterosexual samples were compared on each of the
sociodemographic and cancer characteristic variables of interest. A
1-way ANOVA was conducted with sexual orientation as the
grouping variable for age, with the c2 test for independence used
with frequency data. One-sample t tests were conducted on the
mean scores for criterion and predictor variables to assess differences
between the GB and heterosexual samples and published norms or
other appropriate comparison sample means. Preliminary analyses
for multiple regression analyses included independent sample t tests
to assess group differences in mean scores on the criterion HRQOL
and all potential predictor variables, and Pearson’s correlations to
assess associations between the criterion and predictor variables for
GB and heterosexual samples. Finally, to evaluate the relationship
between the set of potential predictor variables and the criterion,
and identify those variables responsible for the variation in the
criterion, standard multiple linear regression analyses were con-
ducted for the GB and heterosexual samples. Exact alpha levels are
reported for all statistical tests, with table notations indicating sig-
niﬁcance at the 0.05, 0.01, or greater than 0.001 levels where
relevant. Ninety-ﬁve percent conﬁdence intervals (CI) are reported
for effect sizes involving principal outcomes.RESULTS
Study Sample Characteristics
In total, 124 GB and 225 heterosexual men who have, or have
had, PCa were recruited, the majority from within Australia,
with a minority recruited from the United States and the United
Kingdom. Table 1 presents demographics and cancer character-
istics for both samples. GB men compared with heterosexual
men were signiﬁcantly younger (GB 64.25 years; heterosexual
71.54 years), more likely to have completed a university degree
(GB 57%; heterosexual 33%), and less likely to nominate an
Anglo-Celtic ancestry (GB 68%; heterosexual 88%). The
relationship proﬁle of the GB sample differed signiﬁcantly
from the heterosexual sample: GB men were less likely to be
partnered (GB 50%; heterosexual 86%), less likely to report a
current relationship of more than 2-year duration if partnered
(GB 81%; heterosexual 93%), and more likely to have casual
sexual partners (GB 40%; heterosexual 4%). Disease status did
not differ between the GB and heterosexual samples, with the
majority reporting that their cancer was no longer detectable or
in remission. GB men (29%) were less likely to have under-
gone a radical prostatectomy than heterosexual men (38%),
but more likely to have undergone a robotic prostatectomy
(GB 18%; heterosexual 8%), with both samples reporting
similar rates of receiving multiple treatments (GB 29%; het-
erosexual 24%).
Table 1. Sociodemographic and Cancer Characteristics of GB and Heterosexual Men With PCa
Variable
GB Heterosexual Test for group difference
n M (SD) n M (SD) F P h2
Age 119 64.25 (8.18) 224 71.54 (8.98) 55.20 <.001 0.14
Time since ﬁrst diagnosis (y) 115 5.904 (5.03) 213 7.746 (6.81) 6.489 .01 0.02
n % n % c2 P f
Ethnicity
Anglo-Celtic 84 67.74 198 88.00 20.999 <.001 0.192
Other*,† 40 32.26 25 11.11
Employment Status
Fulltime/Part-time 46 37.71 53 23.77 13.32 .001 0.196
Retired/Pension/Social
security
62 50.82 157 70.40
Other 14 11.48 13 5.83
Education
High School 28 22.95 79 35.75 17.23 <.001 0.224
Tertiary diploma or
trade certiﬁcate
25 20.49 68 30.76
University degree or
higher
69 56.55 74 33.48
Relationship status
Partnered (living/not
living together)
60 49.59 175 86.21 51.03 <.001 0.40
Other status/No partner 61 50.41 28 13.79
Length of current relationship
Less than 2 years 13 18.84 13 7.18 7.29 0.01 .171
More than 2 years 56 81.16 168 92.818
Current casual sexual
relationship
Yes 49 39.84 8 3.65 74.250 <.001 0.466
No 74 60.16 211 96.35
Status of disease
No longer detectable 83 68.60 159 71.62 0.62 0.73 0.04
Receiving treatment 36 29.75 61 27.48
Other‡ 2 1.65 2 0.90
Treatment received
Active surveillance 12 10.26 18 8.37 15.16 0.019 0.214
Radical prostatectomy 35 29.06 82 38.14
Robotic prostatectomy 21 17.95 18 8.37
Radiotherapy 15 11.97 37 17.21
Androgen ablation 2 1.71 1 0.47
Hormone therapy 0 0 7 3.26
Multiple treatments
received
34 29.05 52 24.19
*“Other” includes African-American, South-American, South-East Asian, Middle East, each less than 2.4%.
†“Other” includes: Australian Aboriginal less than 0.4%.
‡“Other” includes receiving palliative care or not speciﬁed.
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Relational, Sexuality and Masculine Self-esteem
Measures According to Sexual Orientation
For the outcome variableHRQOL,GBmen reported signiﬁcantly
lower total FACT-P scores than heterosexual men, with this pattern
observed for the “emotional” and “day-to-day” subscales (seeTable 2).Both the GB sample and heterosexual samples reported signiﬁcantly
lower levels of HRQOL in comparison with a post-treatment PCa
sample28 (M¼ 125.1, SD¼ 20.3), t(118)¼ 5.61, P<.001, and
t(209)¼ 4.33, P <.001, respectively.
GB men reported signiﬁcantly higher total psychological
distress than men in the heterosexual sample, with higherJ Sex Med 2016;13:425e434
Table 2. Comparisons on All Variables for GB and Heterosexual Men
Variable
GB Heterosexual Test for group difference
M (SD) M (SD) t (df) P 95% CI h2
QoL (FACT-P)
Social 18.20 (5.99) 19.32 (5.71) 1.69 (335) .091 [2.42-0.18] .008
Physical 23.91 (4.46) 24.42 (4.18) 1.06 (339) .289 [1.46-0.44] .003
Emotional 17.07 (4.48) 18.33 (4.04) 2.58 (230.21) .010 [2.23 to 0.30] .028
Day-to-day 19.99 (6.02) 21.94 (5.90) 2.91 (344) .004 [3.26 to 0.63] .024
Additional 34.52 (7.27) 34.20 (7.55) 0.38 (343) .702 [1.32-1.96] .000
Total 113.96 (21.67) 118.82 (20.99) 1.99 (327) .046 [9.65 to 0.07] .012
Psychological
distress (BSI-18)
Somatization 2.81 (4.12) 2.30 (3.41) 1.19 (216.82) .23 [0.34-1.37] .007
Depression 4.65 (5.40) 2.71 (4.40) 3.41 (214.44) .001 [0.82-3.05] .052
Anxiety 1.95 (2.58) 1.25 (2.20) 2.56 (222.38) .01 [0.16-1.24] .029
Panic 1.27 (2.34) 0.73 (1.88) 2.20 (211.88) .03 [0.06-1.02] .022
Total 10.68 (12.41) 6.98 (10.39) 2.81 (219.10) .005 [1.10-6.28] .034
Cancer-related
distress (MAX-PC)
Prostate Cancer Anxiety 8.45 (7.64) 5.34 (6.56) 3.81 (221.07) <.001 [1.50-4.72] .062
PSA Anxiety 1.02 (1.83) 0.27 (0.91) 4.29 (154.38) <.001 [0.41-1.11] .107
Fear of Recurrence 4.29 (3.08) 3.32 (2.88) 2.91 (344) .004 [0.31-1.62] .024
Total 13.59 (10.56) 8.92 (8.94) 4.15 (216.76) <.001 [2.45-6.90] .073
Sexual functioning
(CSFQ-14-M)
Pleasure 1.74 (1.24) 1.05 (1.17) 5.15 (343) <.001 [0.43-0.96] .002
Sexual Desire/frequency 4.40 (1.97) 2.63 (2.22) 7.59 (271.80) <.001 [1.31-2.23] .175
Sexual desire/interest 7.82 (3.12) 5.43 (3.22) 6.66 (343) <.001 [1.69-3.10] .115
Arousal/erection 3.87 (4.13) 1.93 (2.88) 4.61 (184.65) <.001 [1.11-2.77] .103
Sexual orgasm/ejaculation 4.24 (3.31) 2.33 (2.53) 5.55 (197.45) <.001 [1.23-2.60] .135
Total sexual functioning 29.76 (10.84) 21.01 (9.48) 7.78 (343) <.001 [6.54-10.97] .150
Sexual HRQoL (EPIC)
Function 21.15 (8.65) 16.49 (8.41) 4.90 (347) <.001 [2.79-6.53] .065
Bother 9.48 (5.14) 9.89 (5.21) 0.70 (341) .482 [1.56-0.74] .001
Total 29.63 (12.68) 24.45 (11.56) 3.86 (347) <.001 [2.54-7.81] .041
Sexual communication
(DSCS)
33.31 (12.31) 32.58 (10.96) 0.44 (216) .660 [2.55-4.02] .001
Masculine self-esteem
(PCAQoL)
55.79 (28.41) 66.69 (24.47) 3.54 (219.62) <.001 [16.95 to 4.83] .054
Sexual intimacy
(PCAQoL)
50.72 (31.01) 52.14 (30.58) 0.41 (333) .685 [8.28-5.45] <.001
Sexual conﬁdence
(PCAQoL)
47.92 (29.34) 37.56 (27.55) 3.25 (338) .001 [4.10-16.62] .030
Ejaculatory concern 2.62 (0.10) 1.85 (0.08) 5.99 (331) <.001 [0.51-1.02] .098
Satisfaction with
treatment
2.53 (0.75) 2.73 (0.63) 2.51 (206.81) .013 [0.37 to 0.04] .030
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caseness criteria not used to formally diagnose participants in
this study, GB were more likely to meet the criteria for
distress, 13.7% compared with 7.1% of the heterosexual
sample (c2 (1, 349) ¼ 4.07, P ¼ .04). Psychological distress
for the GB sample was higher compared with UK29 (t(123) ¼
2.47, p¼ 0.015) and U.S. general population norms23 (t(123)¼
4.73, p <0.001). Reports of psychological distress for theJ Sex Med 2016;13:425e434heterosexual sample were higher than USA norms (t(222) ¼
2.28, P ¼ .024), although lower than that found in the GB
sample.
Reports of total PCa-related distress were signiﬁcantly higher
among GB men compared with heterosexual men, although both
samples failed to reach clinical thresholds30 on the PCa anxiety
(>16.5), PSA anxiety (>4.5), and fear of reoccurrence (>6)
subscales.
Table 3. Correlations Between Predictor Variables and QoL:
GBmen and Heterosexual Men With PCa
Variable
GB QoL
(FACT-P)
Heterosexual
QoL (FACT_P)
Age .187* .032
Education Level .122 .197†
Years since diagnosis .093 .002
Psychological
distress (BSI-18)
.768‡ .794‡
Cancer-related
distress (MAX-PC)
.570‡ .520‡
Sexual functioning
(CSFQ-14-M)
.389‡ .256‡
Sexual HRQoL (EPIC) .512‡ .422‡
Sexual Communication
(DSCS)
.262* .301‡
Masculine self-esteem
(PCAQoL)
.683‡ .612‡
Sexual intimacy
(PCAQoL)
.636‡ .529‡
Sexual conﬁdence
(PCAQoL)
.618‡ .453‡
Ejaculatory concern .536‡ .430‡
Treatment
Satisfaction
.499† .299†
*P < .05.
†P < .01.
‡P < .001, one-tailed.
430 Ussher et alRatings of sexual functioning were higher for the GB sample
compared with the heterosexual sample across all subscale and
total scores on the CSFQ-14M. For both samples, scores failed to
reach cutoffs for sexual dysfunction24 across all domains (total
sexual functioning <47; pleasure <4; sexual desire/frequency
<8; sexual desire/interest <11; arousal/excitement <13; and
sexual orgasm/completion <13).Total sexual function (CSFQ)
and sexual HRQOL (EPIC) subscale scores were signiﬁcantly
higher for the GB sample compared with the heterosexual
sample. Despite this difference, both samples were signiﬁcantly
lower in sexual HRQOL compared with age-matched controls
(t(123) ¼ 29.30, P < .001; t(224) ¼ 50.01, P < .001,
respectively).31 On the measure of ejaculatory concern, the GB
sample reported signiﬁcantly more concern than the heterosexual
sample.
Sexual communication scores did not differ signiﬁcantly
between the samples. However, both samples reported signiﬁ-
cantly lower scaled scores (M ¼ 64.06, SD ¼ 23.67; M ¼ 62.65,
SD ¼ 21.07, respectively) compared with a noncancer
sample population25 (M ¼ 81.66, SD ¼ 13.08; t(67) ¼ 6.13,
P < .001; t(149) ¼ 11.05, P < .001, respectively). Masculine
self-esteem scores were signiﬁcantly lower among the GB
sample compared with the heterosexual sample, whereas
sexual conﬁdence scores were signiﬁcantly higher. No difference
between samples was found for reports on sexual intimacy. For
both samples, masculine self-esteem (t(120) ¼ 9.26, P < .001;
t(214) ¼ 7.80, P < .001, respectively) and sexual intimacy
scores (t(121) ¼ 7.05, P < .001; t(212) ¼ 8.76, P < .001,
respectively) were signiﬁcantly lower than a non-PCa male age-
matched sample,25 as were sexual conﬁdence scores for the het-
erosexual sample (t(216) ¼ 4.73, P < .001).
The correlations between all potential predictor variables and
HRQOL measures according to sexual orientation are pre-
sented in Table 3. For both samples, signiﬁcant positive
correlations were observed for treatment satisfaction, sexual
functioning, sexual HRQOL, sexual communication, mascu-
line self-esteem, sexual intimacy, and sexual conﬁdence scores,
whereas psychological distress, PCa-related distress, and ejacu-
latory concern were signiﬁcantly inversely correlated with
HRQOL scores. For the GB sample, higher age (65 years)
was signiﬁcantly positively correlated with HRQOL, with
higher education level signiﬁcantly positively correlated for the
heterosexual sample.Prediction of HRQOL
Evaluations of assumptions were satisfactory, with no outliers
with a standardized residual >3, and no cases found with a
Mahalanobis distance score of P < .001 for all analyses per-
formed. There were no potential predictors with nonsigniﬁcant
0-order correlations (as identiﬁed in Table 3); hence, none were
excluded in the regression analyses. No multicollinearity among
predictors was detected with all correlation coefﬁcients <0.90.
Table 4 displays the unstandardized regression coefﬁcients (B)and intercept, the standardized regression coefﬁcients (b), the
semipartial correlations (sr2), R2, adjusted R2, R, and the conﬁ-
dence limits for signiﬁcant semipartial coefﬁcients. Semipartial
correlation coefﬁcients are a useful measure for interpretation, as
they indicate how much each variable uniquely contributes to
R2 over and above that which can be accounted for by the other
predictor variables.
For the GB sample, the full regression model signiﬁcantly
explained 84% of the variance in total HRQOL scores, F(9,
65) ¼ 24.78, P < .001, adjR2 ¼ 0.84, 95% CI [0.79, 0.89].
Squared semipartial correlations indicate 3 variables contrib-
uted uniquely to the prediction of quality of life scores,
explaining 16% of the variance. The size and direction of the
relationships indicated by the observed standardized regres-
sion coefﬁcients suggests higher levels of HRQOL for GB
men is associated with higher masculine self-esteem and
treatment satisfaction, and lower psychological and PCa-
related distress. For the heterosexual sample, the linear com-
bination of all predictors signiﬁcantly explained 72% of the
variance in total HRQOL scores, F(9, 139) ¼ 37.46, P <
.001, adjR2 ¼ 0.72, 95% CI [0.66, 0.78]. Only 2 predictors
displayed signiﬁcant semipartial correlations, uniquely
explaining 22% of the variance in quality of life scores.
Higher levels of HRQOL in heterosexual men are uniquely
associated with higher sexual conﬁdence and lower levels of
psychological distress.J Sex Med 2016;13:425e434
Table 4. Multiple Regression Predicting FACT-P Total Scores From
Predictor Variables by Sample for Men With Prostate Cancer
Variable
Gay/Bisexual Heterosexual
B b sr2 B b sr2
Age 4.732 .114
Education
Level
1.429 .061
Psychological
distress
(BSI-18)
.861‡ .450 0.09 1.287‡ .612 0.22
Masculine
Self Esteem
(PCaQoL)
.170* .216 0.02 .062 .074
Sexual Intimacy
(PCaQoL)
.077 .101 .013 .019
Sexual Conﬁdence
(PCaQoL)
.072 .097 .104* .144 0.01
Sexual
Communication
(DSC)
.058 .034 .046 .025
Cancer-related
distress
(MAX-PC)
.438† .219 0.03 .136 .059
Sexual Functioning
(CSFQ-Total)
.327 .157 .141 .064
HRQoL: Sexual
(EPIC)
.117 .066 .003 .002
Ejaculatory
concern
.616 .032 1.023 .059
Satisfaction with
treatment
4.549* .176 0.02 2.768 .086
(Intercept) 101.667 108.538
R2 .841§ .716k
Total Adj.
R2
.804 .690
R .917 .846
95% Conﬁdence limits
from 0.79 to 0.89
95% Conﬁdence limits
from 0.66 to 0.78
*P < .05.
†P < .01.
‡P < .001.
§Unique variability ¼ 0.16; shared variability ¼ 0.68.
kUnique variability ¼ 0.23; shared variability ¼ 0.49.
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The ﬁndings of this study conﬁrm previous reports that
PCa is associated with reductions in HRQOL and increased
psychological distress, as well as disruptions to sexual func-
tioning, dyadic sexual communication, masculine self-esteem,
sexual conﬁdence, and sexual intimacy, compared with
matched population norms. Our ﬁndings also conﬁrm previous
reports that GB men experience a different impact of PCa on
HRQOL17,18 as well as greater psychological distress17 and
ejaculatory bother,19 lower masculine self-esteem,18 and greater
dissatisfaction with treatment.17 Findings of higher sexualJ Sex Med 2016;13:425e434functioning and sexual conﬁdence in GB men after PCa also
conﬁrm previous research reports.17
These differences between GB and heterosexual men may be
interpreted in the light of previous suggestions that PCa-related
sexual changes can have a different meaning for GB men,32
associated with the materiality and discursive construction of
gay sex.33 The maintenance of erectile functioning has been re-
ported to be of greater importance for GB men,34 due to the
signiﬁcance of an erect penis in gay sex.33,35 While vaginal
penetration may be possible with a partial erection, anal sex
requires a ﬁrm erection, with estimates suggesting 33% more
rigidity is required.36 Reduction in penis size and absence of
ejaculation also may have greater consequences for GB men, due
to gay men having a preference for partners with a large penis,37
and the erotic and intimate signiﬁcance of semen exchange
during gay male sex.38 The prostate is a pleasure centre for gay
men,12 and therefore loss of pleasure or discomfort during anal
sex following PCa may be a deterrent to men engaging in the
receptive role in anal intercourse.33,39 Some GB men may change
roles in anal intercourse as a means of coping with erectile
difﬁculty.40 However, secondary self-labeling in relation to
preferences in sexual roles during anal intercourse can be an
important aspect of identity for GB men,41 and changing sexual
roles is not always possible or desirable.35,42 The relational
context within which many GB men experience sexual changes
after PCa also may differ from that of heterosexual men, as found
in the present study, with gay men more likely be single,43 and to
engage in casual or concurrent sexual relationships if they are
partnered.44 This has implications for wellbeing and partner
support,11 as intimate partners play a major role in caring,45 as
well as for the negotiation of sexual changes, which may be more
difﬁcult with new or casual partners.33
If GB men are diagnosed and treated at a younger age, as
reported in both the present study and previous research,19 the
consequences of PCa treatment on sexual functioning will be
experienced for a longer period, with potential implications for
HRQOL. It has previously been reported that that PCa-related
ED has a greater impact on younger men,46 reﬂected in posi-
tive association between age and HRQOL in the present study,
which may also contribute to higher rates of psychological
distress and lower HRQOL in GB men. Whereas PCa is
recognized to have an impact on masculinity, gay men also may
experience disruptions to gay identity32,33 with implications for
HRQOL and psychological well-being. This may account for the
ﬁnding that masculine self-esteem was a predictor of HRQOL
for GB men, but not heterosexual men, in the present study.
The results of this study and other recent studies of HRQOL
in GB men with PCa have a number of implications for clini-
cians and researchers working in PCa care. Our ﬁndings reinforce
the importance of sexuality for HRQOL after PCa treatment for
all men. The signiﬁcance of psychological distress as a predictor
of HRQOL in both groups of men, with PCa-related distress
also acting as a predictor for GB men, emphasizes the importance
432 Ussher et alof psychosocial interventions aimed at reducing psychological
and cancer related distress,47 with a long-term aim of improving
HRQOL. The ﬁnding that sexual conﬁdence was a predictor
of HRQOL for heterosexual men, and masculine self-esteem
was a predictor for GB men, suggests that boosting sexual con-
ﬁdence and masculine self-esteem should be central to such
interventions.
GBmenmay have greater unmet needs in terms of psychological
support. For although a plethora of psychological interventions
have been developed for heterosexual men and couples to address
PCA related concerns,47 at present, there is an absence of GB-
speciﬁc health PCa information and counseling, with a few
notable exceptions.48 It has previously been suggested that PCa
health services and information have a heteronormative focus,11
indicating that targeted support services for GB men need to be
developed, and general health service providers need to be sensitive
to the needs and concerns of GB men.49 This includes awareness
and inclusion of GB relational support, attention to GB-speciﬁc
sexual concerns and identity issues after PCa, and avoidance of
heterocentric language in consultations. Experiences of negative
reactions from health professionals to disclosure of GB identity, or
refusal to discuss GB-speciﬁc sexual experiences after PCa,50,51
may contribute to greater dissatisfaction with treatment in GB
men, with implications for HRQOL.
There were a number of strengths and limitations of the
present study. The strengths included the use of a range of
validated psychosocial instruments, the use of comparative
samples of GB and heterosexual men, and the analysis of pre-
dictors of HRQOL, the ﬁrst study in this ﬁeld to undertake such
analysis. The inclusion of gay-speciﬁc wording, such as anal sex
and male partners in the GB sexual instruments is also a strength,
as it addresses the criticism that such instruments exclude or
overlook the sexual practices of men who have sex with men,52
and demonstrates the acceptability of such measures for GB
men with PCa. The limitations include the use of a self-selected
volunteer sample completing online surveys, which may attract
participants who have treatment side effects; the use of multiple
methods of recruitment that did not allow for calculation of
response rate; the heterogeneous and nonmatched nature of the 2
samples, and the absence of inclusion criteria other than PCa
diagnosis, which leads to caution about the comparison; and the
retrospective nature of data collection, which may inﬂuence
recollection of experiences, combined with absence of data from
clinical records, which does not allow for substantiation of in-
formation on diagnosis and treatment. Future research should
ideally recruit through cancer registries or clinical contexts, and
compare matched samples of GB and heterosexual men longi-
tudinally from the point of diagnosis. However, this is difﬁcult at
present, as sexual orientation data is currently not routinely
collected by cancer registries53 and clinics focusing on GB men
with PCa are rare. Matching a heterosexual sample to GB men
recruited through other means is an alternative compromise.
Bisexual men also made up a relatively small proportion of thesample, despite concerted efforts to recruit such men, suggesting
further research is needed in this area. Future research also should
examine the impact of type of treatment, and stage of cancer at
diagnosis, variables not assessed in the present study. Finally, it
would be useful to compare the experiences of GB men with PCa
with GB men who have other types of cancer in order to
elucidate factors that are speciﬁc to GB men across cancers.
In conclusion, this study adds new information and knowledge
to the developing ﬁeld of GB experiences of PCa. Differences
observed between GB and heterosexual men in HRQOL across
the psychological and sexual domains, as well as in satisfaction
with treatment, suggests that GB-speciﬁc PCa information and
support is needed. Routine collection of data on sexual orientation
by cancer registries and clinics will facilitate targeting imple-
mentation of such support, serving to address the needs of this
hitherto “invisible diversity” in the ﬁeld of PCa research and care.
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